9 5 3 6 3
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.3 Breast Cancer (Dove Med Press)
- 3.4 Clin Epidemiol
- 2.5 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.5 Clin Interv Aging
- 4.7 Drug Des Dev Ther
- 2.7 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.5 Int J Women's Health
- 2.5 Neuropsych Dis Treat
- 2.7 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.3 Ther Clin Risk Manag
- 2.5 J Pain Res
- 2.8 Diabet Metab Synd Ob
- 2.8 Psychol Res Behav Ma
- 3.0 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.7 Risk Manag Healthc Policy
- 4.2 J Inflamm Res
- 2.1 Int J Gen Med
- 4.2 J Hepatocell Carcinoma
- 3.7 J Asthma Allergy
- 1.9 Clin Cosmet Investig Dermatol
- 2.7 J Multidiscip Healthc
PD-1/PD-L1 通路抑制剂对头颈癌治疗的现状及发展前景
Authors Ran X, Yang K
Received 28 April 2017
Accepted for publication 13 June 2017
Published 3 July 2017 Volume 2017:11 Pages 2007—2014
DOI https://doi.org/10.2147/DDDT.S140687
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Chiung-Kuei Huang
Peer reviewer comments 3
Editor who approved publication: Dr Tuo Deng
摘要：头颈癌为常见恶性肿瘤，目前传统治疗方式疗效不佳、并发症多，迫切需要发展高疗效和低毒副作用的治疗方法。随着癌症分子生物学及免疫学的发展，针对程序性细胞死亡受体 1（Programmed cell Death 1,
PD-1）和程序性细胞死亡配体（Programmed cell Death 1, PD-L1）的免疫检测点靶向治疗在头颈癌治疗中显示出了巨大的发展前景，特别在治疗复发/转移的头颈部鳞状细胞癌中取得了突破性的进展。本文总结了目前 PD-1 和 PD-L1 靶向药物在头颈癌治疗中的现状，并前瞻性评估 PD-1/PD-L1 分子靶向治疗的前景。
关键词：头颈癌；鳞状细胞；PD-1；PD-L1；免疫治疗；免疫检测点
